BGL Insider: Healthcare & Life Sciences — Urology
1. Introduction
Physician practice management (PPM) continues to be an area of significant interest for a well-capitalized private equity community. As certain sub-specialties like Dermatology and Ophthalmology continue to mature with many consolidators starting combine with one another, the investor community is looking to deploy capital into newer specialties that present significant opportunities for growth. Especially relevant to investors is the notion that healthcare services, in particular providers of care, are more insulated from broader market trends than other opportunities. As the market looks for actionable, high-quality investments in a period of uncertainty and “risk-off” behavior, PPM is a pocket of opportunity given the potential for a slowdown in the broader economy.
Over the last few years, Urology has come into the spotlight for institutional investors. An ancillary-rich specialty with high fragmentation and ample supply and demand tailwinds, Urology is ripe to accelerate its consolidation wave. Investors with not only capital but also relationships and resources to offer can assist urologists with recruiting and facility and equipment investments, while also leveraging technology and extenders to create capacity and managing the business allowing physicians to practice medicine. Much like the dynamics in other specialties, those physicians with interest in creating a platform or joining forces with a strategic partner have those options today.
We expect consolidation activity in Urology to accelerate substantially over the coming years. Large platforms with a foothold in the industry continue to be acquisitive. Additionally, private investors are seeking new platforms in the space. There are still several large Urology groups which could act as platforms and as the complexity of running a practice continues to challenge physicians, BGL expects new platforms to materialize.
This report is intended to highlight tailwinds in the industry, the investor-backed platforms, and commentary from boots-onthe-ground operators.
2. Macro Tailwinds
Aging & Ailing Population
2030 has been called a demographic turning point for the U.S. population, when it is projected that more than one in five Americans will be 65 years and older. The 65-and-older population is projected to reach over 73 million, an increase of nearly 50% from 2016. This aging population is a favorable dynamic to the urology industry, as many patients receive the most care over the age of 65 years.
A growing elderly population coupled with a higher incidence of chronic diseases puts more pressure on healthcare spend. Spending in the hospital and ambulatory surgery centers is expected to continue growing at a rapid pace, exceeding historical averages. This trend is due to an aging population of Medicare and Medicaid beneficiaries.
Statistically, most patients needing urological care are above the age of 65+; therefore, a growing elderly population is a direct correlation to the rising demand for urologists and urology services. More so, urologists have seen an uptick in necessary care of elderly patients compared to previous years due to sedentary and unhealthy lifestyles which are contributing to compounded health conditions and leading to further urological issues. Further, increased technology has vastly extended individual life expectancy, increasing the number of patients demanding urological services exponentially.

A Sharp Rise in The Number of Chronic Illnesses
The United States has seen a sharp increase in the number of chronic illnesses leading to higher rates of hospital visits that often require a urologist to diagnose and treat. Several factors contribute to this overall trend besides an aging population including, but not limited to, tobacco use, poor nutrition, and lack of physical activity, with a high prevalence of chronic urinary disorders owing to sedentary lifestyles.
Not only has age played a significant role in the number of urology visits, but also complications from chronic illnesses that lead to issues prominent in the urology industry. Nearly half (approximately 45%, or 133 million) of all Americans suffer from at least one chronic disease, and that number is growing. Today, one in four U.S. adults have two or more chronic conditions, while more than half of older adults have three or more chronic conditions.
Rising incidence of chronic diseases such as diabetes and obesity are contributing to the growth of the market as these two diseases increase with age and can be contributors to urological conditions, among them bladder cancer and urinary incontinence. An estimated 33% of U.S. adults aged 65 and older have diabetes which has been associated with increased risk for bladder cancer. Bladder cancer occurs mainly in older people, with nine out of ten affected over the age of 55. The average age at diagnosis is 75. Further, bladder cancer is considered one of the most expensive cancers to treat over the lifetime of patients. Obesity prevalence is on the rise; more than 40% of Americans (41.5%) aged 60 and older are obese according to CDC estimates. Studies suggest that each 5-unit increase in body mass index (BMI) is associated with a 60 –100% increased risk of daily urinary incontinence.
Urologic disease is growing in prevalence in the United States. Millions of Americans suffer from urinary incontinence—an estimated quarter to a third of all men and women—according to the Urology Care Foundation. About 33 million have overactive bladder. Benign prostatic hyperplasia (BPH), or prostate enlargement, affects half of all men by age 60, and by 90, reaches 90%. In American men, prostate cancer is the second most common cancer, and bladder cancer is the fourth most common cancer.
3. Micro Tailwinds
Provider Supply / Demand Imbalance
Urology is facing provider supply constraints amid the aging population and rising incidence of chronic disease in the U.S. The industry will need to find ways to leverage the provider base to meet increasing demand for urology services. The industry is ripe for consolidation with the ability to expand ancillary service lines one of the most widely cited drivers of growth and consolidation. Consolidation will allow for leverage of back-office infrastructure, investment in outpatient facilities to drive efficiency, and the ability to leverage technology and physician extenders to meet the demands on the market.
There exists a sharp contrast in geographical location of practicing urologists in the U.S. with only 10.0% practicing in non-metropolitan areas, leaving a majority (62.2%) of counties without urological care.
The shortage of practicing urologists is expected to exceed 3,600 by 2025.


The Urologist Shortage Makes Effective Physician Engagement More Important Than Ever
In the United States, there are over 13,000 urology providers, 51.2% of whom work in private practice. Nearly 40% (38.6%) of private practices have fewer than three urologists, of which 20.2% are solo practitioners. The supply / demand imbalance is exacerbated by the aging population of practicing urologists with 50.0% over the age of 55. This poses a significant challenge to the industry to continue to meet the surging demand from the aging population and growing prevalence of urologic conditions. Further, there are fewer students graduating from residency programs in the urology field each year to combat the imbalance in supply and demand.

Shifting Site of Service – Telehealth
Telehealth is increasingly shifting care delivery, with virtual visits likely to play a long-term role in urological care. Because a vast majority of urologists—90% according to 2022 AUA Census data—practice in metropolitan regions, patient access in rural areas can be difficult. Telehealth bridges that gap and allows patients in rural areas of the country to still receive care. More so, the vast number of patients seeking care from urologists are over the age of 65 and most susceptible to illnesses contracted in a medical environment making telehealth a safer alternative. Further, this opportunity for virtual care urges more people to seek care due to the convenience and safety concerns.
Historically, telehealth was not widely utilized in the urology industry, however, the use of telehealth surged during the COVID-19 pandemic. One ASPE report found that Medicare telehealth use increased 63-fold nationally between 2019 and 2020, for which urology was also a beneficiary.
According to 2020 AUA Annual census data, 71.5% of urologists stated they participated in telemedicine, a dramatic acceleration from only 11.9% utilization the year prior.
While telehealth utilization has since declined from the crisis peak, national rates remain above pre-pandemic levels, with experts predicting the trend to continue as technology and bandwidth become more accessible. Telemedicine in urology spans new patient consultations to telesurgery to post-operative rounds, with increased utilization of APPs likely to support telehealth’s growing adoption by urology practices for patient management. According to 2022 AUA Census data, nearly 65% of practicing urologists in the U.S. saw patients virtually for initial visits, and 82% saw patients virtually for follow-up visits. Forty-two percent of practicing urologists in nonmetropolitan areas reported conducting initial visits virtually and 68.9% for follow-up visits in 2022.
Radiation Oncology
Prostate cancer is the second leading cause of cancer death among American men and is driving the growth of radiation oncology ambulatory centers. Spending for prostate cancer has increased over the past decade and now approaches $12 billion in the U.S. alone. Reasons for the spending growth are likely multifaceted but include the high rates of treatment and dissemination of new options for therapy that have grown due to technology such as robotic surgery, intensity-modulated radiation therapy (IMRT), and proton beam radiation therapy, all of which get more expensive than the prior alternative. Recent trends in the organization of urological practices towards building large single-specialty groups contributes to the increase in prostate cancer spending. Many urology groups have purchased the equipment necessary to develop and monitor IMRT for patients with prostate cancer who are treated by urologists in the group. Taking this into account, urology groups have the potential to collect both the professional and technical revenue from IMRT that otherwise would have been lost to physicians. In other words, IMRT has
a high reimbursement rate.

4. Opportunities & Investors
Urology has seen an initial wave of consolidation with several platforms forming over the past several years. These platforms range in size and strategy from single-state and regional groups to national players. Many are focused on pure play urologic services, but some differentiate specializing in oncology and others as multi-specialty providers layering in gastroenterology primary care, and other services to their offering.
All the aforementioned platforms are active acquirers, capitalized by private equity, and are seeking like-minded groups to partner with in and around their respective geographies. Each brings nuance to partnership with a variety of incentive structures and affiliation models, but all are in pursuit of similar goals to drive growth, create physician autonomy, and deliver high-quality care to the patients they serve.
Over the next two to three years, BGL expects to see several new platforms form around private investment in Urology. In addition, many groups will decide to partner with an existing platform. Overall, we expect a frothy market with high volumes as we push through and out of a potential economic slowdown. Given the nature of the Urology industry and its natural insulation from market pressures, we expect valuations to hold strong throughout this anticipated transaction activity.
Recent Industry Consolidation

5. Executive Perspective
Michael J. Shannon, Chief Executive Officer, First Urology
Mike has been in primary and specialty healthcare management for over 20 years and joined Metropolitan Urology in 2001. As Chief Executive Officer of Metro, he was an integral part of the 2011 merger with Allied Urology. Mike has guided First Urology to become the largest privately owned medical practice in the state of Kentucky.
How do you see demand for urology services changing over the next 5-10 years? How do you see the provision of Urology services changing in conjunction?
Urologic services, at least in this country, is being pulled in two different ways, both negatively. First, you’ve got the baby boomers. We are all living longer, and the longer we live the more we need urologists to take care of us. Just staying in your own market area, you’re going to increase your patient volume. Second, and this has been going on for a while now, but the average age of urologists is going up, not down. Twice as many urologists retire than come out of training each year. So that combination of more patients and fewer urologists is really putting a strain on the system, and it’s not improving.
How do you solve such an imbalance? Mid-levels? Other solutions?
Urologists are going to need to utilize APPs to take care of the patients that can be handled by a midlevel provider. We currently have half as many nurse practitioners as we do urologists, and that’s not enough. We need more. There are a lot of groups that are one for one. That is probably the direction we are heading, so that they hold down the office because obviously the one place that a mid-level provider can’t replace a physician is in the OR. That is where some of the supply shortfall is going to be alleviated.
What are the intangible elements you find are appealing to physician recruits or is recruiting success largely tied to compensation?
First, put the mid-levels aside quickly. It’s about money with them. Look, Urology is one of the highest paid specialties, so money isn’t an issue. We are finding that work life balance is more important with the newer generation of physicians. We are having those conversations with the millennials coming out of training. It’s very much a change in the mindset. You look at the older cohort of physicians who have a
different work ethic. They went into medicine in large part to be entrepreneurial and start a business and take ownership of that business. The new generation is focused on different priorities. I think for the most part, very few are entrepreneurial. It’s the reason there are so many in every field that are gravitating to either academics or to hospital employment models because they just want to practice medicine. They just want to go to work, practice medicine, and go home. They don’t know anything about business. They maybe don’t have a real interest in it.
The only thing that we know for sure is this is the new normal. And we’re going to have to adjust and deal with it for us to continue to be successful.
Has operating the business side of a urology practice become more complex? How so? What are the administrative burdens that are most frustrating?
Staffing probably is everybody’s first answer to that. Finding talent at least at the mid to upper level is not difficult, but certainly at the rank and file, it’s very difficult. Filling that need is more than a full-time job. I mean, I’ll take the next 10 medical assistants that walk in the door. They’re hired. At the same time, the average hourly wage for a medical assistant is going up. In 2019, maybe it was $14 an hour. The average medical assistant is probably making $20 an hour today. And this is Louisville, Kentucky. We’re not Chicago, New York, or LA. So that’s certainly a struggle.
As cost of care continues to be one of the most important elements of the evolution of healthcare in the US, do you continue to see shifts in site of service for procedures and to what extent?
Technology keeps getting better. Skills keep getting better. And it’s better medicine too. Prostatectomy
went from being a big open case and long hospital stay 20 years ago to an outpatient service today. Physicians would prefer everything in the outpatient setting or even in the office. From our vantage
point, it’s strictly about efficiency. They turn rooms around in half the time at a surgery center than they
do at a hospital. You can get twice as many cases done. Now you move cases to the office setting, and it’s even more efficient, but you pay a price and that the reimbursement is a fraction.
How do you feel about the reimbursement outlook for urologic services? Anything imminent? Anything on the horizon keeping you up at night?
Reimbursements go down, so you’re always looking for new revenue streams. For example, PCR, a pathology test for diagnosing complicated UTIs, was introduced four or five years ago. We had an entire room in our path lab devoted to PCR. All the equipment. A trained technologist. About 10 months ago, Medicare designated 28 states as molecular diagnostic states, and they stopped paying for the test. Indiana and Kentucky both were part of those 28 states. A very large revenue stream just came to a halt for us. So, you always have those kinds of fears that those things will happen.
I think that is why you see a lot of privately owned practices either must grow and get to a certain scale or they kind of migrate to hospitals. Because you can’t fight it if you’re a single or a two or a three-person group because you’re not large enough to be able to get the volume for these ancillaries.
How are you deploying ancillaries, facilities, and new technologies in your business?
From a business standpoint, Urology is as strong as any specialty because there are so many ancillary
opportunities. You’ve got imaging, pathology, radiation, surgery centers. More than half of our total
revenue is non [E&M] and surgery revenue.
We have a couple of pathologists to run our path lab. And we have three radiation oncologists running our two radiation centers.
In-office dispensing (IOD) is growing. We’ve had an IOD for about five or six years, and it’s expanding. For example, for our advanced prostate cancer division, the cancer drugs are becoming more and more important, and the numbers are significant. I certainly see pharmacy doing more.
We’ve been in chronic care management (CCM) now for about five or six years, and it’s starting to give way to something called principal care management (PCM). PCM only requires patients o have one complex chronic condition; CCM requires two or more. PCM enables more patients to participate.
We’ve been in clinical research for 15 or 16 years, and that’s a nice ancillary service.
Some urology groups are layering in GI, Oncology, and other adjacent specialties – what are your thoughts on the opportunity here?
We are committed to not branch out into multi-specialty. Given our market share in Louisville, we have an understanding with the hospital networks that we’re not going to be competitors with them. We’re just going to provide quality urologic care for their patients. Provided we do that, they won’t get into Urology.
How do you find the Urology community’s receptivity to private equity investment?
Private equity is impacting the choices that people coming out of residency are making. They all want to know where we stand with private equity. I think the feeling for most of them is that private equity deals are good for the retiring physicians and not good for the new recruits. It is just economics.
“Value based care” is a popular term these days, how do you view the opportunity in Urology?
It has been talked about now for three, four years. I don’t know if we’re any closer to it today. Surprisingly,
the ACO dynamic has not hit our market yet. Maybe we’re just too small of a market that it hasn’t gotten to us yet. We do utilize analytics software to track outcomes in preparation for when value-based care becomes more of an opportunity.
Marshal Salomon, Chief Executive Officer, Unio Health Partners
Mr. Salomon serves as Chief Executive Officer and a member of the Board of Managers of Unio Health Partners. He brings over 25 years of executive leadership experience in multi-site, community-based healthcare organizations to these roles.
How do you see demand for Urology services changing over the next 5-10 years? How do you see the provision of Urology services changing in conjunction?
Urology does benefit from the big demographic plays. Once you get to be of a certain age, Urology becomes a core component of your primary care continuum.
Just like many other specialties, the ability to diagnose and treat a variety of conditions, not just in an outpatient setting but even in clinic, has continued to increase. The diagnostic tools are better. So, there really are an array of services that a urologist can provide in a convenient community setting that remains very attractive to large segments of the population.
Do you see a supply/demand imbalance of providers
relative to patient need?
There is a fundamental imbalance not only in terms of newly minted urologists but also the retirement trajectory of existing urologists, and so they are at a premium.
How do you solve such an imbalance? Mid-levels? Other solutions?
There are three components from our perspective. First is increased thoughtful use of APPs, advanced practice providers. NPs and PAs should be core to the thesis. I think we’ve been able to prove unequivocally over the last several years that an APP in a well-structured group or office can provide tremendous leverage.
Second is efficiency. How do we focus on making physicians more efficient? Thoughtful scheduling. Many practices, even the sophisticated ones, have weak scheduling so there end up being gaps in the schedule. Having a call list of individuals who can come in on short notice if gaps develop in the schedule. Increased use of telehealth, which continues to be well received by physicians and patients and is very cost effective.
The third leg of the stool is you need to offer newly minted physicians a different value proposition from other opportunities.
What are the intangible elements you find are appealing to physician recruits or is recruiting success largely tied to compensation?
Compensation matters. They know they’re a precious commodity. There’s a demand and supply imbalance, so you can’t ignore compensation. Above and beyond that, then it becomes, how do I grow my practice? And that’s where the ability with us to garner ancillary services income —from lab, pharmacy, chronic care, radiation oncology, clinical trials—becomes of real interest. Obviously in a small practice, you’re just not getting that. Even in a medium-sized practice, you might have some of it, but you’re not at scale.
Has operating the business side of a urology practice become more complex? How so? What are the administrative burdens that are most frustrating?
There really are practice management challenges that are just harder than ever. Physician recruitment, practice expansion, and succession planning can be incredibly challenging. Contracting? You’re a price taker as a small practice under all circumstances. There are technology needs— EMR, revenue cycle, IT, cybersecurity.
As practices get to that point where the administrative burdens are overwhelming and the necessity to continue to invest is similarly challenging, those obviously become candidates to work with us. We’ll take the administrative burden off their plate, we’ll monetize some of the economics, and we’ll allow them to pivot back to being physicians first and foremost.
As cost of care continues to be one of the most important elements of the evolution of healthcare in the US, do you continue to see shifts in site of service for procedures and to what extent?
Hospitals are an incredibly valuable part of the broader healthcare ecosystem, but there are more and more services that can and should be provided in cheaper, convenient community settings.
Assuming the shift will continue, how do you balance your relationship with the hospital?
We want to work with the hospitals. I think you can craft a pretty good relationship as long as you’re both recognizing that you’re more valuable working collaboratively with each other rather than competing. In the well-functioning relationships, the hospitals look to the community physicians a little less adversarially.
How do you feel about the reimbursement outlook for urologic services? Anything imminent? Anything
on the horizon keeping you up at night?
The five-year outlook for Urology is maybe modestly down but not materially so.
Some Urology groups are layering in GI, Oncology, and other adjacent specialties. What are your thoughts on the opportunity here?
We’re proving it every day. We’ve managed GI and Radiation Oncology along with Urology since inception, and are thrilled with our recent affiliation with inSite Digestive Health.
It’s a thoughtful and strategic way of building an ecosystem and diversifying the portfolio across multiple specialties. It’s still in the early stages, but I do think you’re going to see more and more of this.
How do you find the Urology community’s receptivity to private equity investment?
Fear of private equity has dissipated materially. Like anything, it’s a little bit fear of the unknown, but the more real data points you have, the more empirical it becomes in terms of demonstrably generating value.
I would suggest there are an increasing number of physicians who are looking for these opportunities. They want to remain in the community. There is recognition by physicians that the headwinds are increasing. They are thinking, my upside is limited. It’s all based on my dayto-day efforts. I really wish I could drive some ancillary income into my practice. Now they can work with an organization that is demonstrably credible, that there’s this way of building longterm wealth and monetizing many years’ worth of effort. I think that’s very attractive and generally supersedes any sort of generic concern about what private equity might represent.




















